Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Neuroblastoma clinical trials
Every US clinical trial registered for Refractory Neuroblastoma — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
10 US clinical trials · 7 currently recruiting
The research picture
Refractory Neuroblastoma has 10 registered US clinical trials, 7 of them open to new participants right now — about 70% of the total.
- 7
- recruiting participants now
- 70%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Stephan Grupp MD PhD
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
NCT06721689
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Stephan Grupp MD PhD
NCT05650749
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Roberto Chiarle
NCT06803875
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Stephan Grupp MD PhD
NCT07007117
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Nationwide Children's Hospital
NCT04211675
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Emory University
NCT05400603
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Steven DuBois, MD
NCT07027748
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
NCT03794349
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
NCT03635632
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
NCT01711554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Refractory Neuroblastoma Trial Landscape
ClinicalTrials.gov lists 10 US studies indexed under Refractory Neuroblastoma, and 7 of those are currently open to recruitment — roughly 70% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Refractory Neuroblastoma shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 10 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Refractory Neuroblastoma is led by Stephan Grupp MD PhD with 2 indexed trials, alongside 8 other organizations in the top contributor list. The list on this page surfaces up to 10 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Refractory Neuroblastoma?
PlainTrial tracks 10 US clinical trials for Refractory Neuroblastoma, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Refractory Neuroblastoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.